aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, has announced the granting of inducement stock options to three new employees. The Compensation Committee approved options to purchase 62,400 shares at $5.71 per share, matching the closing price on September 3, 2025.
The options, granted under Nasdaq Listing Rule 5635(c)(4) and the company's 2022 Inducement Plan, vest over four years with 25% vesting after one year and the remaining 75% vesting monthly over three years. aTyr focuses on developing first-in-class medicines from its tRNA synthetase platform, with efzofitimod as its lead candidate for treating interstitial lung disease.
aTyr Pharma (Nasdaq: ATYR), societ脿 biotecnologica in fase clinica, ha comunicato l'assegnazione di stock option di incentivazione a tre nuovi dipendenti. Il Comitato per la Remunerazione ha approvato opzioni per l'acquisto di 62.400 azioni a $5,71 per azione, pari al prezzo di chiusura del 3 settembre 2025.
Le opzioni, concesse ai sensi della regola Nasdaq 5635(c)(4) e del Piano di Induzione 2022 dell'azienda, maturano in quattro anni: il 25% dopo un anno e il restante 75% mensilmente nei successivi tre anni. aTyr 猫 focalizzata sullo sviluppo di farmaci di prima classe dalla sua piattaforma di aminoacil-tRNA sintetasi, con efzofitimod come candidato principale per il trattamento delle malattie polmonari interstiziali.
aTyr Pharma (Nasdaq: ATYR), una biotecnol贸gica en fase cl铆nica, ha anunciado la concesi贸n de opciones sobre acciones por incentivo a tres nuevos empleados. El Comit茅 de Compensaci贸n aprob贸 opciones para comprar 62.400 acciones a $5,71 por acci贸n, equivalente al precio de cierre del 3 de septiembre de 2025.
Las opciones, otorgadas conforme a la Norma de Cotizaci贸n Nasdaq 5635(c)(4) y al Plan de Inducci贸n 2022 de la compa帽铆a, vencen durante cuatro a帽os: el 25% tras el primer a帽o y el 75% restante en pagos mensuales durante los tres a帽os siguientes. aTyr se centra en desarrollar medicamentos innovadores a partir de su plataforma de aminoacil-tRNA sintetasa, siendo efzofitimod su candidato principal para el tratamiento de la enfermedad pulmonar intersticial.
aTyr Pharma (Nasdaq: ATYR), 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 旮办梾鞚� 靹� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞙犾澑靹� 鞀ろ啞鞓奠厴鞚� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 氤挫儊鞙勳洂須岆姅 62,400欤�毳� 欤茧嫻 $5.71鞐� 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴鞚� 鞀轨澑頄堨溂氅�, 鞚措姅 2025雲� 9鞗� 3鞚� 膦呹皜鞕� 霃欖澕頃╇媹雼�.
頃措嫻 鞓奠厴鞚� Nasdaq 靸侅灔攴滌爼 5635(c)(4) 氚� 須岇偓鞚� 2022 鞚鸽崟靺� 頂岆灉鞐� 霐半澕 攵�鞐悩鞐堨溂氅�, 4雲� 霃欖晥 靹膘垯頃╇媹雼�: 1雲� 頉� 25%臧� 氩犾姢韺�霅橁碃 雮橂ǜ歆� 75%電� 頄ロ泟 3雲勱皠 鞗旊硠搿� 氩犾姢韺�霅╇媹雼�. aTyr電� tRNA 頃╈劚須唽 頂岆灚韽检潉 旮半皹鞙茧 頃� 斓滌磮鞚� 鞁犾暯 臧滊皽鞐� 欤茧牓頃橁碃 鞛堨溂氅�, efzofitimod臧� 臧勳靹� 韽愳頇� 旃橂毳� 鞙勴暅 欤检殧 頉勲炒氍检鞛呺媹雼�.
aTyr Pharma (Nasdaq: ATYR), une soci茅t茅 de biotechnologie en phase clinique, a annonc茅 l'attribution d'options d'incitation 脿 trois nouveaux employ茅s. Le comit茅 de r茅mun茅ration a approuv茅 des options d'achat de 62 400 actions au prix de 5,71 $ par action, correspondant au cours de cl么ture du 3 septembre 2025.
Les options, accord茅es en vertu de la r猫gle Nasdaq 5635(c)(4) et du Plan d'Inducement 2022 de la soci茅t茅, se acqui猫rent sur quatre ans : 25 % apr猫s un an et les 75 % restants mensuellement sur les trois ann茅es suivantes. aTyr se concentre sur le d茅veloppement de m茅dicaments de premi猫re classe 脿 partir de sa plateforme d'aminoacyl-ARNt synth茅tase, efzofitimod 茅tant son principal candidat pour le traitement des maladies pulmonaires interstitielles.
aTyr Pharma (Nasdaq: ATYR), ein Biotech-Unternehmen in klinischer Phase, hat die Gew盲hrung von Incentive-Aktienoptionen an drei neue Mitarbeiter bekanntgegeben. Das Verg眉tungskomitee genehmigte Optionen zum Kauf von 62.400 Aktien zu $5,71 pro Aktie, entsprechend dem Schlusskurs vom 3. September 2025.
Die unter Nasdaq-Listing-Regel 5635(c)(4) und dem Inducement-Plan 2022 des Unternehmens gew盲hrten Optionen laufen 眉ber vier Jahre: 25% nach einem Jahr und die verbleibenden 75% monatlich 眉ber die folgenden drei Jahre. aTyr konzentriert sich auf die Entwicklung von First-in-Class-Medikamenten aus seiner tRNA-Synthetase-Plattform, wobei efzofitimod der f眉hrende Kandidat zur Behandlung interstitieller Lungenerkrankungen ist.
- Company maintains ability to attract talent with equity compensation
- Structured vesting schedule helps retain employees over 4-year period
- Potential dilution to existing shareholders from new stock options
- Additional stock-based compensation expense impact on financial statements
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (鈥渁Tyr鈥� or 鈥渢he Company鈥�), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr鈥檚 Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr鈥檚 common stock, each with an exercise price of
Each option vests over a period of four years, with
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr鈥檚 discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr鈥檚 lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit .
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
FAQ
What stock options did aTyr Pharma (ATYR) grant to new employees in September 2025?
How do the vesting terms work for aTyr Pharma's September 2025 inducement grants?
What is aTyr Pharma's main therapeutic candidate?
What is the purpose of aTyr Pharma's inducement grants under Nasdaq Rule 5635(c)(4)?
